Sequential cleavage of poly(ADP-ribose)polymerase and appearance of a small Bax-immunoreactive protein are blocked by Bcl-X(L) and caspase inhibitors during staurosporine-induced dopaminergic neuronal apoptosis by �옣�씤�씡
Sequential Cleavage of Poly(ADP-Ribose)polymerase and
Appearance of a Small Bax-Immunoreactive Protein Are
Blocked by Bcl-XL and Caspase Inhibitors During
Staurosporine-Induced Dopaminergic Neuronal Apoptosis
Ji-Eun Kim, Jae H. Oh, Won-Seok Choi, In I. Chang, *Seonghyang Sohn, †Stanislaw Krajewski,
†John C. Reed, ‡Karen L. O’Malley, and Young J. Oh
Department of Biology, College of Science, Yonsei University, Seoul; *Laboratory of Cell Biology, Institute for Medical Science,
Ajou University, Suwon, Korea; †Burnham Institute, La Jolla, California; and ‡Department of Anatomy and Neurobiology,
Washington University School of Medicine, St. Louis, Missouri, U.S.A.
Abstract: To assess the role of Bcl-XL and its splice
derivative, Bcl-XS, in staurosporine-induced cell death,
we used a dopaminergic cell line, MN9D, transfected with
bcl-xL (MN9D/Bcl-XL), bcl-xS (MN9D/Bcl-XS), or control
vector (MN9D/Neo). Only 8.6% of MN9D/Neo cells sur-
vived after 24 h of 1 mM staurosporine treatment.
Caspase activity was implicated because a caspase in-
hibitor, N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl
ketone (Z-VAD-fmk), attenuated staurosporine-induced
cell death. Bcl-XL rescued MN9D cells from death (89.4%
viable cells), whereas Bcl-XS had little or no effect. Bcl-XL
prevented morphologically apoptotic changes as well as
cleavage of poly(ADP-ribose)polymerase (PARP) induced
by staurosporine. It is interesting that a small Bax-immu-
noreactive protein appeared 4–8 h after PARP cleavage
in MN9D/Neo cells. The appearance of the small Bax-
immunoreactive protein, however, may be cell type-spe-
cific as it was not observed in PC12 cells after stauro-
sporine treatment. The sequential cleavage of PARP and
the appearance of the small Bax-immunoreactive protein
in MN9D cells were blocked either by Z-VAD-fmk or by
Bcl-XL. Thus, our present study suggests that Bcl-XL but
not Bcl-XS prevents staurosporine-induced apoptosis by
inhibiting the caspase activation that may be directly or
indirectly responsible for the appearance of the small
Bax-immunoreactive protein in some types of neurons.
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Apoptosis is a highly conserved form of cell death that
might have evolved as a regulatory mechanism for de-
velopment, cellular homeostasis, and certain pathologi-
cal conditions (Wyllie, 1993; Thompson, 1995). It is
typically accompanied by a series of characteristic mor-
phological and biochemical changes such as cytoplasmic
shrinkage, membrane blebbing, chromatin condensation,
and DNA laddering into oligonucleosomal-sized double-
stranded fragments. Neuronal cell death is also a prom-
inent feature of vertebrate development (Oppenheim,
1991). Depending on the location, ;20–80% of neurons
in a given developing population die, possibly by apo-
ptotic processes. Furthermore, accumulating evidence
indicates that particular sets of neuronal cells associated
with neurodegenerative diseases such as Alzheimer’s,
Huntington’s, and Parkinson’s disease die of apoptosis
(Su et al., 1994; Portera-Cailliau et al., 1995; Stern,
1996). Therefore, it is of clinical interest to investigate
the mechanism(s) underlying neuronal cell death associ-
ated with such devastating diseases in the CNS.
Among many proposed mechanisms, activation of in-
terleukin-1-b-converting enzyme (ICE)-like proteases
seems to be a required element of apoptotic cell death in
many paradigms (Martin and Green, 1995). It has been
demonstrated that ICE has significant sequence homol-
ogy to Ced-3, first identified as a positive regulator of
cell death during the development of the nematode Cae-
norhabditis elegans (Yuan et al., 1993). Overexpression
of ICE in fibroblasts resulted in apoptosis (Miura et al.,
1993). Subsequently, involvement of ICE in neuronal
cell death was demonstrated in vertebrates (Gagliardini
et al., 1994). These findings have been followed by the
discovery of several ICE/Ced-3-like homologues, re-
cently termed caspases (Alnemri et al., 1996). Proteolytic
activation of one caspase may lead to proteolytic pro-
cessing of the next caspase involved, resulting in a cas-
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cade of protease activation (Martin and Green, 1995).
Diverse cellular proteins, including poly(ADP-ribose)-
polymerase (PARP), serve as substrates for these cas-
cades of caspase activation (Cryns and Yuan, 1998). In
addition to caspases, overexpression of several other
proteases was also shown to be associated with apoptotic
death. These include granzyme B, chymotrypsin, pro-
teinase K, and trypsin (Shi et al., 1992; Williams and
Henkart, 1994). It is interesting that granzyme B, a serine
protease, initiates apoptosis by proteolytic processing
and activation of ICE/Ced-3 proteases in hemopoietic
cell types (Darmon et al., 1995). This raises the possi-
bility that there may exist several other pathways in
which the temporal interaction among many different
proteases is centrally regulated during apoptosis in cer-
tain cell types.
Numerous recent findings have demonstrated that
Bcl-2 acts as a negative regulator of apoptosis induced
by various stresses (Reed, 1997). Several other members
of the Bcl-2 family have also been identified. For exam-
ple, Bcl-XL, one member of the Bcl-2 family, is the
major form of bcl-x mRNA expressed during embryonic
and postnatal development of murine tissues (Boise et
al., 1993; Gonzalez-Garcia et al., 1994). Like Bcl-2, its
233-amino acid product has been shown to localize to the
mitochondrial outer membrane and perinuclear envelope.
As a result of alternative splicing of bcl-x mRNA,
Bcl-XS encodes a 178-amino acid protein, which lacks a
stretch of internal 63 amino acids that make up the region
of highest homology to Bcl-2. Overexpression of Bcl-XL
can prevent apoptosis, whereas expression of Bcl-XS
enhances apoptotic cell death in several cases (Boise et
al., 1993). Many Bcl-2 family members, including Bcl-
XL, show widespread expression in the developing and
adult brain (Merry and Korsmeyer, 1997). The physio-
logical role of these proteins in neuronal life and death
has been shown in many neuronal cell types of the CNS.
However, their roles have not been extensively explored
in dopaminergic neuronal cell death, which is intimately
associated with the development of Parkinson’s disease.
A wide range of cell types, including dopaminergic
neuronal cells, undergo apoptosis after treatment with a
broad-spectrum protein kinase inhibitor, staurosporine
(Jacobson et al., 1993; Oh et al., 1997). Therefore, we set
out in the present experiments to characterize further
staurosporine-induced cell death and to elucidate the
effects of Bcl-XL and Bcl-XS on the survival of murine
dopaminergic neuronal cells following staurosporine
treatment. Comparisons were made with a pan-caspase
inhibitor, N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl
ketone (Z-VAD-fmk).
MATERIALS AND METHODS
Cell culture and drug treatments
MN9D cells stably transfected with a eukaryotic expression
vector, CMV/bcl-xL (MN9D/Bcl-XL), CMV/bcl-xS (MN9D/
Bcl-XS), or control CMV/Neo (MN9D/Neo), were established
and maintained. To test the effects of staurosporine, cells from
each clone were plated at a density of 2 3 104 cells on 25
mg/ml poly-D-lysine-coated 48-well plates (Corning) and main-
tained in Dulbecco’s modified Eagle’s medium supplemented
with 10% heat-inactivated fetal bovine serum (GibcoBRL) and
250 mg/ml G-418 (complete culture medium) for 3 days in an
incubator with an atmosphere of 10% CO2 at 37°C. Cells were
subsequently switched to serum-free N2 medium containing
the various experimental reagents and further incubated for the
indicated intervals. Reagents included staurosporine (0.25–1.0
mM; Sigma), iodoacetamide (2.5–10 mM; Sigma), Z-VAD-fmk
(100 mM; Enzyme Systems Products), and cycloheximide
(0.25–1.0 mg/ml; Sigma).
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) reduction assay
Following incubation with various experimental reagents,
the rate of cell survival was assessed by colorimetric measure-
ment of MTT reduction, which is an indicator of the pyridine
nucleotide redox state of the cell, as described previously
(Shearman et al., 1994). In brief, after the indicated incubation
times, the MTT solution was added to a final concentration of
1 mg/ml, and the cells were incubated for 2 h at 37°C, followed
by lysis in 20% sodium dodecyl sulfate in 50% aqueous N,N-
dimethylformamide for 24 h. The optical density of the dis-
solved formazan grains within the cells was measured at 540
nm on a microplate reader (Molecular Devices). Values from
each treatment were calculated as a percentage relative to
untreated control (100% survival).
Electron microscopy
Both MN9D/Neo and MN9D/Bcl-XL cells plated at a den-
sity of 7.0 3 104 on poly-D-lysine-coated 24-well plates were
treated with 1.0 mM staurosporine for various intervals. After
various incubation times (up to 24 h of treatment), cells were
fixed in 2% paraformaldehyde and 2% glutaraldehyde in 0.1 M
cacodylate buffer (pH 7.4) for at least 12 h at 4°C and then
postfixed in 1% osmium tetroxide/1.5% ferrocyanide solution
for 30 min at room temperature. Cells were dehydrated in a
graded series of ethanols, embedded in Epon resin, and heat-
polymerized. Epon blocks were cut using a Reichert–Jung
Ultracut S (Leica) and double-stained with uranyl acetate and
lead citrate. Sections were examined using a Zeiss EM 902A
transmission electron microscope.
Immunoblot analysis
For the characterization of stable cell lines, 5–10 3 106
MN9D/Neo, MN9D/Bcl-XL, and MN9D/Bcl-XS cells were
washed with ice-cold phosphate-buffered saline and lysed on
ice in a lysis buffer containing 50 mM Tris (pH 7.0), 2 mM
EDTA, 1.0% Triton X-100, 2 mM phenylmethylsulfonyl fluo-
ride, and 10 mg/ml aprotinin. Subsequently, lysates were cen-
trifuged at 13,000 g for 10 min. The protein content of the
resulting supernatant was measured using the Bio-Rad protein
assay kit. For analyzing PARP and Bax, MN9D/Neo, MN9D/
Bcl-XL, MN9D/Bcl-XS, and PC12 cells were plated at a density
of 1 3 106 on poly-D-lysine-coated P-100 culture plates (Corn-
ing) and grown in complete culture medium for 3 days before
drug treatment. At the various times indicated, cells were
incubated in a lysis buffer and further processed for immuno-
blot analysis as described above. Equal amounts of soluble
protein (40–75 mg) were separated on 10% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis gels. Proteins were
transblotted onto prewetted polyvinylidene difluoride-nitrocel-
lulose filters (Bio-Rad). Primary antibodies used were rabbit
polyclonal anti-Bcl-X, which recognizes both Bcl-XL and
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Bcl-XS forms (1:3,000); mouse monoclonal anti-PARP (1:
10,000; a generous gift from Dr. G. G. Poirier); rabbit poly-
clonal anti-mouse Bax, raised against amino acid residues
43–61 of mouse Bax [1:2,000 (Krajewski et al., 1994)]; and
rabbit polyclonal anti-Bax directed against amino acid residues
11–30 (N-20, 1:1,000; Santa Cruz). Specific bands of interest
were detected by enhanced chemiluminescence (ECL; Amer-
sham) as recommended by the manufacturer.
RESULTS
Characterization of Bcl-XL- and Bcl-XS-expressing
MN9D cell lines by immunoblotting
To assess the potential role of Bcl-XL and Bcl-XS in
the dopaminergic neuronal cell line MN9D, cells were
transfected with CMV/bcl-xL (MN9D/Bcl-XL), CMV/
bcl-xS (MN9D/Bcl-XS), or the parental vector CMV/Neo
(MN9D/Neo). Two separately derived clonal cell lines
expressing the highest mRNA levels of bcl-xL and two
for bcl-xS were selected through RT-PCR (data not
shown) and further analyzed by immunoblot analysis.
The analysis demonstrated that MN9D/Bcl-XL clone 14
contained higher levels of protein than clone 22, whereas
Bcl-XS clone 40 expressed higher levels of the Bcl-XS
protein than clone 25 (Fig. 1A).
Characterization and quantification of
staurosporine-induced cell death
Staurosporine treatment induced cell death in MN9D/
Neo cells as determined by the MTT reduction assay.
Approximately half of the MN9D/Neo cells died 10–12
h following 1 mM staurosporine treatment. When treated
with 0.25–1.0 mM staurosporine for 24 h, cells from
MN9D/Bcl-XL clone 14 remained viable following stau-
rosporine treatment (Fig. 1B). Similar patterns were ob-
served in MN9D/Bcl-XL clone 22 (data not shown). The
two MN9D/Bcl-XS clones, on the other hand, showed
cell death patterns relatively similar to that of MN9D/
Neo cells, regardless of the level of Bcl-XS expression.
When morphological changes were examined by light
microscopy, treatment of cells with staurosporine ini-
tially resulted in neurite arborization within 4–6 h (data
not shown; Oh et al., 1997). Thereafter, MN9D/Neo cells
exhibited typical apoptotic changes such as shrinkage of
the cytoplasmic membrane and nuclei (Fig. 2B). Stauro-
sporine treatment led to the degeneration of neurite ar-
borizations of MN9D/Neo cells as well. Quite similar
patterns of morphological changes were observed in the
two MN9D/Bcl-XS cells (data not shown). It is interest-
ing that both MN9D/Bcl-XL clone 14 and clone 22 cells
displayed more rounded cell bodies even before drug
treatment (Fig. 2D; data not shown for clone 22). Fol-
lowing staurosporine treatment, MN9D/Bcl-XL cells
maintained extensive arborization of neurites, yet there
was no blebbing of the plasma membrane, retaining
intact cell bodies and nuclei even after 24 h of treatment
(Fig. 2E). When their viability was assessed by the in situ
MTT reduction assay, the majority of surviving MN9D/
Bcl-XL cells showed dark formazan grains within the
cytoplasm, demonstrating that the mitochondria of these
cells were still functionally intact (Fig. 2F; compare with
MN9D/Neo cells in Fig. 2C).
Electron microscopic analysis of staurosporine-
induced morphology
To examine the ultrastructural changes during stauro-
sporine-induced cell death in greater detail, both MN9D/
Neo and MN9D/Bcl-XL clone 14 cells were treated with
1 mM staurosporine for various times and analyzed by
electron microscopy. Within 4–6 h of treatment, stauro-
sporine induced the appearance of perinuclear chromatin
condensation in a few MN9D/Neo cells (data not
shown). By 16–24 h, the majority of shrunken MN9D/
Neo cells exhibited chromatin condensation, which was
sharply delineated around the inner surface of the nuclear
envelope and was often accompanied by nuclear convo-
lution (Fig. 3B). In some cells, nuclear fragments of
varying size and chromatin content were obvious. Cyto-
plasmic organelles, including mitochondria and endo-
plasmic reticulum, remained largely intact. However,
MN9D/Bcl-XL cells treated with 1 mM staurosporine for
up to 24 h displayed no discernible changes typical of
apoptosis observed in MN9D/Neo cells (Fig. 3C; com-
pare with untreated control shown in Fig. 3A).
Sequential cleavage of PARP and appearance of a
small Bax-immunoreactive protein
Previously, it has been shown that PARP cleavage by
activated caspases is one of the common events associ-
FIG. 1. Overexpression of Bcl-XL protects cells from staurospo-
rine-induced cell death. A: Immunoblot analysis of MN9D stable
cell lines overexpressing Bcl-XL (MN9D/Bcl-XL ), Bcl-XS (MN9D/
Bcl-XS), or vector alone (MN9D/Neo). MN9D cells were trans-
fected, selected, expanded, and characterized using polyclonal
antibodies recognizing both Bcl-XL and Bcl-XS forms of the
protein. B: MTT reduction assay following staurosporine treat-
ment. Cells from MN9D/Bcl-XL clone 14 (), MN9D/Bcl-XS clone
25 ({), clone 40 (n ), or MN9D/Neo (F) cells were treated with the
indicated concentrations of staurosporine for 24 h. Viability was
measured by the MTT reduction assay. Values from each treat-
ment group were expressed as a percentage relative to the
untreated matching control (100%). Data are mean 6 SEM (bars)
values from three or four independent cultures done in triplicate.
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ated with many cases of apoptosis (Lazebnik et al., 1994;
Cryns and Yuan, 1998). We therefore performed an
experiment to assess whether staurosporine induces
cleavage of PARP in MN9D/Neo cells and also whether
overexpression of Bcl-XL blocks this event. Both
MN9D/Neo and MN9D/Bcl-XL cells were treated with 1
mM staurosporine for various times. As shown in Fig.
4A, the formation of the 85-kDa cleaved PARP fragment
was seen as early as 12 h in MN9D/Neo cell lysates and
continued thereafter. In the course of examining the
expression level of cell death-associated proteins, we
found that our antibodies against Bax recognized both
the intact 21-kDa Bax and a smaller band of 18 kDa that
appeared at least 4–8 h after PARP cleavage during the
process of staurosporine-induced cell death (Fig. 4B).
The intensity of this 18-kDa band increased while in
parallel that of the intact 21-kDa Bax band decreased
over time after exposure of cells to staurosporine. In
certain experiments, this 18-kDa band appeared within
2–4 h after PARP cleavage (data not shown). The gen-
eration of the cleaved fragment of PARP was abolished
in MN9D/Bcl-XL but not MN9D/Bcl-XS cells (Fig. 5A).
Similarly, the small Bax-immunoreactive band was seen
in staurosporine-treated MN9D/Neo and MN9D/Bcl-XS
cells, whereas this band was completely abolished in
MN9D/Bcl-XL cells (Fig. 5B).
Properties of the small Bax-immunoreactive protein
When cells were treated with up to 1 mg/ml cyclohex-
imide, a protein synthesis inhibitor, together with stau-
rosporine, appearance of the 18-kDa Bax-immunoreac-
tive band was still observed (Fig. 6A). As shown in Fig.
6B, this 18-kDa band was not detected by an antibody
directed against the N-terminal amino acid residues 1–30
of Bax, whereas the intensity of the intact 21-kDa band
decreased over time, suggesting that it may be a cleaved
form of Bax. Treatment of MN9D/Neo cells with 5 mM
iodoacetamide did not prevent staurosporine-induced
cell death (Fig. 7A). Similarly, staurosporine-induced
cleavage of PARP was not blocked in the presence of
iodoacetamide (data not shown). In contrast, treatment
with 100 mM Z-VAD-fmk markedly attenuated stauro-
sporine-induced cell death (12.6 vs. 64.3% cell survival),
suggesting that the activation of Z-VAD-fmk-sensitive
but iodoacetamide-insensitive cysteine protease(s) is im-
plicated in this cell death model. Although there existed
FIG. 2. Bcl-XL blocks apoptotic cell death but not neurite arborization induced by staurosporine treatment. MN9D/Neo (A–C) and
MN9D/Bcl-XL clone 14 (D–F) cells were plated, maintained, treated with 1 mM staurosporine for up to 24 h, and subsequently
photographed under a Carl Zeiss Axiovert phase-contrast microscope. Photomicrographs were obtained from (A and D) untreated
control cells, (B and E) 1 mM staurosporine-treated cells at 24 h, and (C and F) 1 mM staurosporine-treated cells at 24 h followed by in
situ MTT reduction assay. Note formazan grains within the cytoplasm of virtually all MN9D/Bcl-XL cells reflecting the fact that the
mitochondria of these cells are still functionally intact. Bar 5 50 mm.
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a lag period of at least 4–8 h following cleavage of
PARP, the appearance of the 18-kDa band was blocked
in the presence of 100 mM Z-VAD-fmk but not iodoac-
etamide (Fig. 7B). It is interesting that this 18-kDa band
did not appear in PC12 cells up to 6–12 h after stauro-
sporine treatment, although .80% of PC12 cells died of
apoptosis under these conditions (Fig. 8).
DISCUSSION
Our studies have demonstrated a protective role for
Bcl-XL in staurosporine-induced apoptosis of a dopami-
nergic neuronal cell line. Protection of staurosporine-
induced apoptosis by Bcl-XL overexpression was con-
firmed not only by the quantitative measurement of de-
hydrogenase activity of active mitochondria but also by
the examination of cellular morphology using both light
and electron microscopy. Our present studies have also
shown that overexpression of Bcl-XL possibly affects
processes at or upstream of caspase activation because
Bcl-XL blocked the sequential cleavage of PARP and the
appearance of a small Bax-immunoreactive protein in
FIG. 3. Electron micrographs show that Bcl-XL inhibits apoptotic
changes following staurosporine treatment. Both MN9D/Neo
and MN9D/Bcl-XL clone 14 cells were treated with 1 mM stau-
rosporine for up to 24 h and photographed under a Zeiss EM 902
transmission electron microscope: (A) untreated MN9D/Neo
cells, (B) staurosporine-treated MN9D/Neo cells at 24 h, and (C)
staurosporine-treated MN9D/Bcl-XL at 24 h. Note cellular shrink-
age and perinuclear chromatin condensation typical of apopto-
sis in MN9D/Neo but not in MN9D/Bcl-XL cells following drug
treatment. Bar 5 2.5 mm.
FIG. 4. Cleavage of PARP is followed by the appearance of an
18-kDa Bax-immunoreactive protein following staurosporine
treatment. MN9D/Neo cells were treated with 1 mM staurospo-
rine. At the indicated intervals, cells were lysed and processed
for immunoblot analysis as described in Materials and Methods.
Specific bands of (A) PARP and (B) Bax were detected with
mouse monoclonal antibody raised against PARP (1:10,000, a
generous gift from Dr. G. G. Poirier) and polyclonal antibodies
raised against amino acid residues 43–61 of mouse Bax [1:2,000
(Krajewski et al., 1994)], respectively. Note the appearance of a
small Bax-immunoreactive band at least 4–8 h after PARP
cleavage in this particular set of experiments.
FIG. 5. Sequential cleavage of PARP and the appearance of the
18-kDa Bax-immunoreactive protein are blocked by Bcl-XL but
not by Bcl-XS. MN9D/Neo, MN9D/Bcl-XL clone 14, and MN9D/
Bcl-XS clone 40 cells were treated with 1 mM staurosporine for
the indicated intervals. Immunoblot analysis was performed as
described in Fig. 4. Both (A) PARP cleavage and (B) appearance
of the 18-kDa Bax-immunoreactive band were blocked by
Bcl-XL but not by Bcl-XS.
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staurosporine-treated MN9D cells. That Z-VAD-fmk but
not iodoacetamide was able to block cell death and its
accompanying PARP cleavage in our cell line raises the
possibility that the cysteine protease responsible for cell
death in MN9D cells may be different from the proteases
implicated in nonneuronal systems (Kaufmann et al.,
1993; Casciola-Rosen et al., 1994), perhaps analogous to
the recently proposed protein homologous to human
caspase-3 in the rat brain (Ni et al., 1997).
During the course of staurosporine treatment, both
MN9D/Neo and MN9D/Bcl-XL cells initially went
through similar morphological changes such as neurite
arborization and formation of neuritic varicosities. In the
later stages, however, MN9D/Bcl-XL cells were able to
maintain the integrity of their rounded cell bodies, with-
out accompanying shrinkage of cytoplasmic membrane
and nuclei. As it has been recently demonstrated that
Bcl-XL promotes cell survival by regulating the electrical
and osmotic homeostasis within the cells (Vander Hei-
den et al., 1997), the intrinsic ability of Bcl-XL in regu-
lating the trafficking of various ions somehow results in
better survival after staurosporine treatment, which pos-
sibly disturbs a balance of ions critical for cell life and
death. It is interesting that even before drug treatment, a
clear difference in morphology was observed between
MN9D/Neo and MN9D/Bcl-XL clones in that MN9D/
Bcl-XL cells displayed a more round morphology (com-
pare Fig. 2A with D). Because Bcl-XL has been shown to
form ion channels in membranes (Muchmore et al.,
1996; Minn et al., 1997), perhaps the rounded morphol-
ogy observed in these cells reflects the role of Bcl-XL as
a regulator of ion fluxes, causing an increased ratio of
cell volume to cell area within MN9D cells and possibly
increasing the threshold required for effective cell death
stimulation.
It is interesting that overexpression of Bcl-XS did not
enhance staurosporine-induced apoptosis, unlike results
from some other cell death systems (Boise et al., 1993;
Dole et al., 1996; Ealovega et al., 1996; Pena et al.,
1996). Similarly, acceleration of cell death by Bcl-XS
was not observed in MN9D cells following treatment
with various other drugs, including 1-methyl-4-phe-
nylpyridinium ion, 6-hydroxydopamine, and etoposide
(data not shown). Considering the previous finding that
the expression of bcl-xS mRNA and Bcl-XS protein was
undetectable in developing mouse tissues and experi-
FIG. 7. Both cell death and the appearance of the 18-kDa Bax-
immunoreactive band are blocked by Z-VAD-fmk but not by
iodoacetamide (IAA). MN9D/Neo cells were treated with 1 mM
staurosporine (STS) alone or with 100 mM Z-VAD-fmk (Z-VAD) or
5 mM IAA for 24 h. A: Viability was measured by the MTT
reduction assay. Values from each group were expressed as a
percentage relative to the untreated matching control (100%).
Data are mean 6 SEM (bars) values from two or three indepen-
dent cultures done in triplicate. B: Immunoblot analysis was
performed using polyclonal antibodies raised against amino acid
residues 43–61 of Bax as described in Fig. 4. C, control.
FIG. 8. Staurosporine does not induce the appearance of the
small Bax-immunoreactive protein in PC12 cells. PC12 cells
were treated with 1 mM staurosporine for the indicated intervals.
A: Viability was measured by MTT reduction assay. Values from
each group were expressed as a percentage relative to the
untreated matching control (100%). Data are mean 6 SEM (bars)
values from three independent cultures done in triplicate. B:
Immunoblot analysis was performed using polyclonal antibodies
raised against amino acid residues 43–61 of Bax as described in
Fig. 4.
FIG. 6. Properties of the 18-kDa Bax-immunoreactive band. A:
MN9D/Neo cells were treated with 1 mg/ml cycloheximide (CHX;
a protein synthesis inhibitor), together with 1 mM staurosporine
(STS) for the indicated intervals. Immunoblot analysis for Bax
was performed using polyclonal antibodies raised against amino
acid residues 43–61 of Bax. B: Following treatment of MN9D/
Neo cells with 1 mM STS for the indicated intervals, immunoblot
analysis was carried out using rabbit polyclonal antibodies di-
rected against the N-terminal amino acid residues 11–30 of Bax
(Santa Cruz).
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mentally induced cell death of PC12 cells (Gonzalez-
Garcia et al., 1994; Maroto and Perez-Polo, 1997), it is
reasonable to assume that the physiological role of Bcl-
XS, if any, may be highly restricted.
We have found that an 18-kDa Bax-immunoreactive
band appeared in staurosporine-induced apoptosis. In
agreement with previous reports suggesting that Bax
may be cleaved in cells following treatment with cyto-
toxic agents or infection with viruses (Thomas et al.,
1996; Grandgirard et al., 1998), our experiments using
cycloheximide, a protein synthesis inhibitor, or N-termi-
nal-specific antibodies against Bax make it less likely
that this smaller form of Bax represents a Bax-related
protein that is newly synthesized during cell death in
MN9D cells (see Fig. 6). If this is the case, the stauro-
sporine-induced 18-kDa band appears to be a product of
specific proteolysis, because there is no smeared pattern
of protein as judged from immunoblot analysis by so-
dium dodecyl sulfate–polyacrylamide gel electrophore-
sis. It is intriguing that our finding that this 18-kDa band
does not appear in staurosporine-treated PC12 cells in-
dicates that the appearance of this band is not a common
event associated with apoptosis and may be cell type-
dependent.
It is important that we have also found that the ap-
pearance of the 18-kDa Bax-immunoreactive band is
delayed by a few hours relative to PARP cleavage in
staurosporine-treated MN9D cells. The finding that the
sequential cleavage of PARP and the appearance of the
18-kDa Bax-immunoreactive band were blocked by
treatment with Z-VAD-fmk makes it quite likely that the
activation of the caspase responsible for PARP cleavage
is directly or indirectly responsible for the activation of a
downstream protease. This could be ascribed to the ac-
tivation loop of proteases that eventually leads to the
appearance of the 18-kDa band in staurosporine-induced
MN9D cell death. As the N and C termini of Bax contain
putative target sites for caspases, one at FIQD332R and
another at WIQD1542Q, it may be that the 18-kDa band
is a direct product of caspase-mediated cleavage of 21-
kDa Bax. Our study using antibodies directed against the
N-terminal amino acid residues 11–30 of Bax indicates
that the potential cleavage site is located at the N termi-
nus of Bax. Considering the recent finding that there
exists a stringency of substrate recognition motifs for
known caspases (Thornberry et al., 1997), the possibility
cannot be ruled out, however, that activation of the
noncaspase following Z-VAD-sensitive caspase activa-
tion results in N-terminal cleavage of Bax in MN9D
cells. To understand the underlying significance of this
event it remains to be determined whether the 18-kDa
Bax-immunoreactive protein itself may play any func-
tional role in the effector and/or degradation phases of
apoptosis, analogous to that recently proposed for
cleaved Bcl-2 (Cheng et al., 1997; Grandgirard et al.,
1998).
Recently, neuronal apoptosis has been proposed to be
associated with Parkinson’s disease (Mochizuki et al.,
1996; Anglade et al., 1997; Tompkins et al., 1997). Thus,
our dopaminergic neuronal system may provide a model
for evaluating the mechanism(s) underlying the func-
tional role of Bcl-2-related family members in neuronal
apoptotic cell death. Furthermore, studies of antiapo-
ptotic genes, including Bcl-XL, may suggest strategies
for improving the treatment of patients with Parkinson’s
disease (Thompson, 1995).
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